• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Re-Vana Therapeutics appoints new COO, VP of R&D

February 23, 2021 By Sean Whooley

Re-Vana Therapeutics announced today that it appointed Michael Nash as chief commercial officer and David Shima as VP of R&D.

Belfast, Northern Ireland-based Re-Vana’s two new executives are set to help the company develop its sustained-release therapies for ophthalmic indications, including neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and glaucoma, according to a news release.

Re-Vana’s platform includes EyeLief and OcuLief, which have the potential to produce at least six months of sustained delivery of large molecule biologics. The company has also secured the rights to a novel nanoparticle, polymer-based drug delivery technology for ophthalmic applications.

“I am delighted to welcome both Mike and David to the Re-Vana team,” Re-Vana Therapeutics CEO Michael O’Rourke said in the release. “Their significant U.S. and European ophthalmic drug development and commercialization experience, particularly in the areas of sustained-release technologies as well as biologics and small molecules, will be a major strategic asset as we advance our product portfolio.”

Nash, a veteran of more than 35 years in early-stage, venture-backed drug delivery, medical device and molecular diagnostic companies, previously served as EVP at Oculex Pharmaceuticals, which Re-Vana said is the first company to develop a biodegradable drug delivery system.

“It is a very exciting time to join Re-Vana,” Nash said.  “Sustained release ocular technology has been a strong passion of mine for many years. I am delighted to join the world-class Re-Vana team consisting of employees, scientific advisors and investors.”

Shima will serve as a visiting scholar to Queens University Belfast in addition to his new role at Re-Vana. He previously worked as a consultant to ocular-focused biopharmaceutical companies and held executive roles at Eyetech Pharmaceuticals, Jerini Ophthalmic, Roche and Thrombogenics.

“It is a remarkable opportunity to be able to join Re-Vana to advance the sustained delivery of biologics and small molecules,” Shima said. “I look forward to working with an incredibly dynamic and experienced team to achieve our major strategic goals within ophthalmology.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Personnel, Personnel Moves, Re-Vana Therapeutics

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS